Patents by Inventor Mark Michael Wong

Mark Michael Wong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY
    Publication number: 20240018258
    Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRP?Fc is enhanced in the presence of daratumumab. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
    Type: Application
    Filed: August 30, 2023
    Publication date: January 18, 2024
    Applicant: Pfizer Inc.
    Inventors: Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Mark Michael WONG, Jeffrey Todd WINSTON, Robert Adam UGER
  • CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY
    Publication number: 20210040224
    Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRP?Fc is enhanced in the presence of daratumumab. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 11, 2021
    Inventors: Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Mark Michael WONG, Jeffrey Todd WINSTON, Robert Adam UGER
  • IMPROVEMENTS IN CD47 BLOCKADE THERAPY BY EGFR ANTIBODY
    Publication number: 20210040219
    Abstract: CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and an EGFR antibody such as cetuximab. The anti-cancer effect of cetuximab is enhanced in the presence of SIRP?Fc. Specific combinations include SIRP?Fc forms that comprise an Fc that is either IgGl or preferably IgG4 isotype. These combinations are useful particularly to treat solid tumours and blood cancers including lymphomas, leukemias and myelomas.
    Type: Application
    Filed: March 8, 2019
    Publication date: February 11, 2021
    Inventors: Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Mark Michael WONG, Robert Adam UGER
  • CD47 BLOCKADE THERAPY
    Publication number: 20200157179
    Abstract: CD47+ disease cells, such as various cancers, are treated using a combination of CD47 blockade with T cell checkpoint inhibition. Preferred embodiments use SIRP?Fc in combination with a PD-1 pathway inhibitor such as nivolumab and/or a CTLA-4 inhibitor such as ipilimumab.
    Type: Application
    Filed: March 27, 2018
    Publication date: May 21, 2020
    Applicant: Trillium Therapeutics Inc.
    Inventors: Gloria Hoi Ying LIN, Natasja Nielsen VILLER, Lisa Danae Schultz JOHNSON, Mark Michael WONG, Robert Adam UGER
  • MACROPHAGE STIMULATION IN CD47 BLOCKADE THERAPY
    Publication number: 20190091290
    Abstract: Blockade of the CD47/SIRPa pathway depletes cancer cells. This anti-cancer activity is enhanced when macrophage stimulating agents are used in combination with the CD47 blockade drug. This anti-cancer combination therapy is particularly effective when the CD47 blockade drug is SIRPaFc.
    Type: Application
    Filed: April 13, 2017
    Publication date: March 28, 2019
    Inventors: Gloria Hoi Ying Lin, Natasja Nielsen Viller, Lisa Danae Schultz Johnson, Mark Michael Wong, Robert Adam Uger